Key molecules mediating radio-resistance in glioblastoma multiforme (GBM) have been identified by GCB scientists. The important finding has already garnered much attention from the medical community all over the world in the short time since its announcement. GBM is treated by radiation therapy combined with chemotherapy, but the five-year survival rate is less than 7 percent even with this procedure. By some unknown mechanisms, GBM quickly gains resistance to radiotherapy. Now, a team of scientists from Hokkaido University and Stanford University have revealed a critical process by which this happens. Two main molecules, Rab27b and epiregulin, were identified which interact to contribute to GBM radio-resistance. By revealing the roles that these molecules play, the GCB has exposed a possible target for treatment of this aggressive cancer of the brain. One that could significantly increase the survival rate for GBM. The research was published in the journal Neuro-Oncology Advances.   <Original Article> Soichiro Nishioka, et al. Rab27b contributes to radioresistance and exerts a paracrine effect via epiregulin in glioblastoma. Neuro-Oncology Advances. August 8, 2020. DOI: 10.1093/noajnl/vdaa091